WIN Consortium--challenges and advances.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.Pathology oncology research : POR · 2016
   Trial
2. Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.JCO global oncology · 2026
   Review
3. A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.Therapeutic advances in medical oncology · 2023
   Article
4. Mouse hospital and co-clinical trial project--from bench to bedside.Nature reviews. Clinical oncology · 2015
   Review
5. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
   Article
6. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.The oncologist · 2013
   Article
7. Molecular prescreening to select patient population in early clinical trials.Nature reviews. Clinical oncology · 2012
   Review
8. Somatic variation and cancer: therapies lost in the mix.Human genetics · 2011
   Review
9. Predictive, personalized, preventive, participatory (P4) cancer medicine.Nature reviews. Clinical oncology · 2011
   Review

Corrections and comments

• Comment on
  Methodological and practical challenges for personalized cancer therapies.2011

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as